Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older

BACKGROUND: To determine the efficacy of an adjuvanted recombinant zoster vaccine in reducing the herpes zoster (HZ) burden of illness, HZ burden of interference with activities of daily living, and HZ impact on quality of life. METHODS: The assessments were integrated in two Phase III trials, ZOE-5...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Gerontol A Biol Sci Med Sci
Main Authors: Curran, Desmond, Oostvogels, Lidia, Heineman, Thomas, Matthews, Sean, McElhaney, Janet, McNeil, Shelly, Diez-Domingo, Javier, Lal, Himal, Andrews, Charles, Athan, Eugene, Berglund, Johan, Campora, Laura, de Looze, Ferdinandus, Korhonen, Tiina, Leung, Edward, Levin, Myron, Volpi, Antonio, Johnson, Robert W
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2019
Assuntos:
The Journal of Gerontology: Translational Section
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6625590/
https://ncbi.nlm.nih.gov/pubmed/29955836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/gerona/gly150
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares